RISULTATI DEL TRATTAMENTO PROLUNGATO DEL MORBO DI PARKINSON CON L'ASSOCIAZIONE L DOPA + BENSERAZIDE

M. Casacchia; C. Barba; S. Ruggieri; A. Zamponi; A. Agnoli

RISULTATI DEL TRATTAMENTO PROLUNGATO DEL MORBO DI PARKINSON CON L'ASSOCIAZIONE L DOPA + BENSERAZIDE

Translated title of the contribution: Results of long term treatment of Parkinson's disease with levodopa plus benserazide

M. Casacchia, C. Barba, S. Ruggieri, A. Zamponi, A. Agnoli

www.neuromed.it

Research output: Contribution to journal › Article › peer-review

Abstract

The reasons why treatment of Parkinson's disease with the combination L Dopa+decarboxylase inhibitor ('Benserazide') is better than with L Dopa alone are presented. Experimental and clinical results obtained by other authors with this combination drug are extensively reported. Observations on the treatment of 45 Parkinsonian patients with 'Madopar' (L Dopat 'Benserazide') for a period up to 3 yr are reported. Thirty seven patients had a moderate to good improvement in their symptomatology, 8 other patients showed a slight response to the treatment. An appreciable improvement was shown in tremor, which was scarcely influenced by L Dopa alone. A satisfactory stability of the therapeutic effectiveness was observed during 3 yr. 'Peripheral' side effects were minimized by the combination drug, 'central' side effects were only slightly less frequent in comparison with those reported with L Dopa alone.

Translated title of the contribution	Results of long term treatment of Parkinson's disease with levodopa plus benserazide
Original language	Italian
Pages (from-to)	303-330
Number of pages	28
Journal	Rivista di Neurologia
Volume	44
Issue number	5
Publication status	Published - 1974

ASJC Scopus subject areas

Clinical Neurology

Access to Document

Fingerprint Dive into the research topics of 'Results of long term treatment of Parkinson's disease with levodopa plus benserazide'. Together they form a unique fingerprint.

Cite this

@article{00d4d2b389564ed0beb8bfc97e16dcff,

title = "RISULTATI DEL TRATTAMENTO PROLUNGATO DEL MORBO DI PARKINSON CON L'ASSOCIAZIONE L DOPA + BENSERAZIDE",

abstract = "The reasons why treatment of Parkinson's disease with the combination L Dopa+decarboxylase inhibitor ('Benserazide') is better than with L Dopa alone are presented. Experimental and clinical results obtained by other authors with this combination drug are extensively reported. Observations on the treatment of 45 Parkinsonian patients with 'Madopar' (L Dopat 'Benserazide') for a period up to 3 yr are reported. Thirty seven patients had a moderate to good improvement in their symptomatology, 8 other patients showed a slight response to the treatment. An appreciable improvement was shown in tremor, which was scarcely influenced by L Dopa alone. A satisfactory stability of the therapeutic effectiveness was observed during 3 yr. 'Peripheral' side effects were minimized by the combination drug, 'central' side effects were only slightly less frequent in comparison with those reported with L Dopa alone.",

author = "M. Casacchia and C. Barba and S. Ruggieri and A. Zamponi and A. Agnoli",

year = "1974",

language = "Italian",

volume = "44",

pages = "303--330",

journal = "Rivista di Neurologia",

issn = "0035-6344",

publisher = "Il Pensiero Scientifico Editore s.r.l.",

number = "5",

}

TY - JOUR

T1 - RISULTATI DEL TRATTAMENTO PROLUNGATO DEL MORBO DI PARKINSON CON L'ASSOCIAZIONE L DOPA + BENSERAZIDE

AU - Casacchia, M.

AU - Barba, C.

AU - Ruggieri, S.

AU - Zamponi, A.

AU - Agnoli, A.

PY - 1974

Y1 - 1974

N2 - The reasons why treatment of Parkinson's disease with the combination L Dopa+decarboxylase inhibitor ('Benserazide') is better than with L Dopa alone are presented. Experimental and clinical results obtained by other authors with this combination drug are extensively reported. Observations on the treatment of 45 Parkinsonian patients with 'Madopar' (L Dopat 'Benserazide') for a period up to 3 yr are reported. Thirty seven patients had a moderate to good improvement in their symptomatology, 8 other patients showed a slight response to the treatment. An appreciable improvement was shown in tremor, which was scarcely influenced by L Dopa alone. A satisfactory stability of the therapeutic effectiveness was observed during 3 yr. 'Peripheral' side effects were minimized by the combination drug, 'central' side effects were only slightly less frequent in comparison with those reported with L Dopa alone.

AB - The reasons why treatment of Parkinson's disease with the combination L Dopa+decarboxylase inhibitor ('Benserazide') is better than with L Dopa alone are presented. Experimental and clinical results obtained by other authors with this combination drug are extensively reported. Observations on the treatment of 45 Parkinsonian patients with 'Madopar' (L Dopat 'Benserazide') for a period up to 3 yr are reported. Thirty seven patients had a moderate to good improvement in their symptomatology, 8 other patients showed a slight response to the treatment. An appreciable improvement was shown in tremor, which was scarcely influenced by L Dopa alone. A satisfactory stability of the therapeutic effectiveness was observed during 3 yr. 'Peripheral' side effects were minimized by the combination drug, 'central' side effects were only slightly less frequent in comparison with those reported with L Dopa alone.

UR - http://www.scopus.com/inward/record.url?scp=0016150258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016150258&partnerID=8YFLogxK

M3 - Articolo

C2 - 4217465

AN - SCOPUS:0016150258

VL - 44

SP - 303

EP - 330

JO - Rivista di Neurologia

JF - Rivista di Neurologia

SN - 0035-6344

IS - 5

ER -